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Background: Ganglioglioma (GG) and pilocytic astrocytoma (PA) represent the most frequent low-grade gliomas
(LGG) occurring in paediatric age. LGGs not amenable of complete resection (CR) represent a challenging subgroup
where traditional treatments often fail. Activation of the MAP Kinase (MAPK) pathway caused by the BRAFV600E
mutation or the KIAA1549-BRAF fusion has been reported in pediatric GG and PA, respectively.
Case presentation: We report on a case of BRAFV600E mutated cervicomedullary GG treated with standard
chemotherapy and surgery. After multiple relapse, BRAF status was analyzed by immunohistochemistry and
sequencing showing a BRAFV600E mutation. Treatment with Vemurafenib as single agent was started. For the first
time, a radiological and clinical response was obtained after 3 months of treatment and sustained after 6 months.
Conclusion: Our experience underline the importance of understanding the driver molecular alterations of LGG
and suggests a role for Vemurafenib in the treatment of pediatric GG not amenable of complete surgical resection.
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Ganglioglioma (GG) and pilocytic astrocytoma (PA) repre-
sent the most frequent low-grade gliomas (LGG) occur-
ring in paediatric age. When complete resection (CR) is
obtained, the prognosis of these tumours is excellent. If
CR is not safely achievable, the management can be ex-
tremely challenging and often ineffective despite chemo
and/or radiotherapy, leading to a worse prognosis.
Activation of the MAP Kinase (MAPK) pathway has
been shown to be the main molecular alteration present
in LGG and can be caused by duplication or mutation of
the BRAF gene [1]. In PA the most frequent genetic al-
teration consists in a duplication of the 7q34 region
leading to a KIAA1549-BRAF fusion protein that is con-
stitutively active whereas in GG the BRAFV600E muta-
tion is more frequent. Inhibitors of MAPK pathway have
been considered as a potential target therapy for these
tumours [2,3]. Among such inhibitors Vemurafenib, a* Correspondence: elisabetta.ferretti@uniroma1.it
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unless otherwise stated.competitive small molecule that selectively recognizes
the ATP binding domain of the BRAFV600E mutant, has
proved effective in the treatment of metastatic melanoma,
a neoplasm frequently mutated for BRAF. More recently,
an activity of this drug was proved also in pediatric
BRAFV600E mutated malignant astrocytomas [4-6].
Herein, we report on a case of BRAFV600E mutated cer-
vicomedullary LGG successfully treated with Vemurafenib
as single agent after failure of conventional treatment.
Case report
A 28-month-old boy was transferred to our emergency
department from a local hospital in assisted ventilation
for a respiratory insufficiency in June 2009. MRI per-
formed during diagnostic work up revealed a bulky mass
with cystic component extending from medulla into cer-
vical spinal cord to C5 and dislocating the pons, the
floor of the IV ventricle, the cerebellar vermis and ton-
sils (Figure 1A). As gross total resection (GTR) was not
considered feasible, surgical decompression and a biopsy
of the exophitic portion of the lesion were performed
revealing a LGG with features compatible with PA.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Serial MRI features of the lesion. Sagittal T2 weighted images show, at onset, a bulky mass extending from medulla into cervical
spinal cord, dislocating the pons, the floor of the IV ventricle, the cerebellar vermis and tonsils (A); increased size of both cystic and solid
component of the lesion after surgical decompression and chemotherapy (B); a new disease progression three months after second surgery (C);
further increase of cystic components (D); a relevant reduction in size of both the solid and the cystic components of the lesion six months after
the start of treatment (E).
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episodes of oxygen desaturation >4% of central origin.
Tracheotomy was performed and chemotherapy accor-
ding to the SIOP LGG 2004 protocol started. Unfortu-
nately, the tumour did not respond to treatment showing
a gradual clinical and radiological progression with wors-
ening of the nocturnal episodes of desaturation and pro-
gressive increase of size of both a cystic portion of the
lesion and the solid component (Figure 1B). A second sur-
gery was performed in 2012 in order to reduce the cystic
component of the lesion. The histological examination ofFigure 2 Tumor histology at second biopsy. (A) At the second biopsy,
cells (arrow) in the mist of bland astrocytic cells. (B) The ganglion cells sho
illustrate BRAF V600E (GTG/GAG) mutation detection (arrow) in tumor DNAthe residual lesion showed the presence, in addition to the
glial component, of mature ganglion cells, leading to a
diagnosis of ganglioglioma (GG) (Figure 2) with classical
morphology, i.e. neoplastic astrocytes and ganglion cells
with dysplastic, binucleated neuron, embedded in tissue
with eosinhophilic granular body and lymphocytic intratu-
moral infiltrate. MRI 3 months after surgery revealed a
new disease progression with evidence of multicystic
component in the brainstem and cervical spine, which
appeared to be related to syringobulbia and syringomye-
lia secondary to cerebrospinal fluid outflow impairmentthe neoplasm showed the presence of clusters of mature ganglion
wed strong immunoreactivity for synaptophysin (C). Electropherogram
derived from formalin-fixed paraffin-embedded specimens.
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component, a new attempt of debulking was performed;
intraoperative brainstem monitoring showed functional
responses in the context of the solid component of the
tumour and further resection was then abandoned. Two
syringe-subarachnoid stents were then inserted to achieve
decompression of the cysts. Unfortunately, after an initial
stabilization, slow clinical and radiological progression
were documented (Figure 1D) and the child began to ex-
perience swallowing difficulties and worsening of noctur-
nal oxygen desaturations. Radiotherapy was not advised
due to patient? s age and proton beam therapy was not
deemed feasible due to extension of disease in a critical
location.
Considering the progressive clinical deterioration of
the patient and the absence of other effective options,
molecular testing for evaluation of a target therapy was
performed on the tumour tissue from the first biopsy:
according to data from the literature, the KIAA-BRAF
fusion gene detection and BRAFV600E testing were per-
formed on fresh frozen (FF) tumor tissue by RT-PCR,
PCR amplification and subsequent sequencing.
DNA was extracted from FF tissue specimen using
the QIAamp DNA Mini Kit, as described by the manu-
facturer (Qiagen S.A., Courtaboeuf France). Total RNA
was extracted from FF tissue using Eurogold Trifast (by
Euroclone). DNA and RNA concentrations were quan-
tified using the Nanodrop ND-1000 UV ? vis spectro-
photometer (Labtech France, Palaiseau, France) and the
integrity of nucleic acid was determinated using Quanti-it
RNA Assay kit and quanti-dsDNA BR assay kit with
Quibit fluorometer (by Invitrogen- Life Technologies).
Final products were stored at −20?C until use.
Moreover standard diagnostic procedure were per-
formed. Sections were stained with ematoxilin and eosin,
and immunohistochemical stain for synaptophysin (Mouse
Monoclonal Antibody Synaptophysin diluition 1:200,
Novocastra Clone 27G12), was performed on paraffin sec-
tion using labelled strepavidin-biotin peroxidise technique.
Antigen retrieval was effected by pressure cooking in cit-
rate buffer pH6. The sections was counterstained with
hematoxilin.
KIAA1549:BRAF fusion-gene by sequencing
Reverse-transcription polymerase chain reaction (RT-PCR)
was performed on 1 μg of total RNA using High Capacity
cDNA Reverse Transcriptionkit (Life Technologies) accor-
ding to the manufacturer ? s protocol. The integrity of the
resulting cDNA was checked by amplifying the wild-type
locus of the BRAF gene (in exon 6 / 7) and then submitted
to PCR with specific pairs of primers flanking the fusion
point between the KIAA1549 (in exon 15 or 16) and BRAF
(in exon 9 or 11) genes as described by Jones et al. [7]. The
purified PCR products were then sequenced using theBigDye Terminator v1.1 Cycle Sequencing Kit (Applied
Biosystems, Courtaboeuf, France) with the forward and
reverse primer used to perform the PCR. Sequencing
was performed using the ABI 3130 XL DNA analyser
(Applied Biosystem). The sequences of primers used were
as follows: KIAA1549 exon 15: 5′-CGG AAA CAC CAG
GTC AAC GG-3′; KIAA1549 exon 16: 5′-AAA CAG
CAC CCC TTC CCA GG-3′; BRAF exon 9: 5′-CTC CAT
CAC CAC GAA ATC CTT G-3′; BRAF exon 11: 5′-GTT
CCA AAT GAT CCA GAT CCA TTC-3′. RT-PCR from
RNA didn ? t show the presence of the KIAA1549-BRAF
fusion gene (data not shown).
BRAFV600E mutation analysis
Mutational analysis was performed amplifying DNA with
the primers as follows: BRAF exon 15, 5′- TCA TAATGC
TTG CTC TGA TAG GA-3′ (sense) and 5′-GGC CAA
AAA TTT AAT CAG TGG A-3′ (antisense). The PCR
products were purified using the automated system Bio-
mek NXp by Beckman Coulter and Agentcourt AMPure
XP reagents. Purified products were submitted to PCR
cycle sequencing conditions as follow: denaturation at
95?C for 30 s, annealing at 50?C for 15 s, and extention
at 60?C for 240 s. The cycle sequencing products were
purified using the same automated system and Agent-
court Clean SEQ reagents. Sequencing analysis was per-
formed using the ABI 3130 XL DNA analyser (Applied
Biosystem). DNA analysis sequencing revealed BRAFV600E
mutation (Figure 2C).
Based on these results, a treatment with Vemurafenib
was started on compassionate use in November 2013
(240 mg, 370 mg/m2, twice a day (BID), equivalent to
the minimal dose that proved active in the adult cohort).
The therapy was overall well tolerated: accurate derma-
tological and ECG monitoring were performed and no
ECG changes nor skin lesions were observed. The only
side effect reported was a transient grade 3 Common
Toxicity Criteria (version 4) skin rash that resolved spon-
taneously. MRI performed 3 months after the start of
treatment revealed, for the first time, a reduction in size of
both the solid and the cystic components of the disease, a
trend confirmed after 6 months of treatment (Figure 1E).
Accordingly, clinical symptoms improved with complete
restoration of the swallowing function and reduction of
the nocturnal episodes of desaturation.
Discussion
Gangliogliomas are rare, well-differentiated, neuroepi-
thelial tumors that most commonly affect children and
young adults. They occur more commonly in the supra-
tentorial region, mostly in the temporal lobe (up to 85%),
but can occasionally develop also in the brainstem, cer-
ebellopontine angle, thalamus, optic nerve and spinal
cord. Included in the broad category of LGG, they are
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survival [8].
Surgery is generally recognized as the treatment of
choice for GGs, aimed at achieving a safe complete
tumour resection [9]. Accordingly, the location of the
tumour has also an impact on the PFS, influencing the
management of the disease and the possibility of achiev-
ing a radical surgery [10]. On these bases, LGGs occur-
ring along the midline (chiasma/hypothalamus, basal
ganglia and brainstem) display a poorer outcome as
compared to tumours in other locations, with a higher
risk of disease progression and an indolent course, result-
ing in a high OS [11]. The role of chemotherapy in the
treatment of LGG is still debated: several approaches have
been evaluated showing variable response rates with sub-
stantially low 5-years PSF [12]. Despite these results, to
date it represents the only available approach to delay RT
in younger children with unresectable LGG.
Radiotherapy (RT) is considered the treatment of choice
for LGG not amenable of surgical resection, therefore
representing the best option for centrally located tumours
[13,14]. Unfortunately, adverse effects preclude its use in
younger children (until at least 5, possibly 8 years of age),
leading to a substantial increase in the risk of progression
for this category of patients. Moreover, even when used in
older children, long term vasculopathy, hearing loss and
neurocognitive and endocrinological sequelae remain a
relevant concern [15]. Therefore, taking into consideration
the natural history of tumour stabilization, its indolent
course and the high likelihood of long-term survival, the
use of RT must be carefully weighed.
Our child presented with a rare cervicomedullary GG.
Although the histology resulted favorable, the location
and the age of the child represented relevant negative
prognostic factors, preventing complete surgical removal
of the lesion and the use of RT. In order to obtain a sta-
bilization of the disease, standard chemotherapy based
on SIOP LGG 2004 protocol was administered. Unfor-
tunately, but not surprisingly, the child clinically and
radiologically progressed at the end of the treatment,
confirming the indolent but progressive course of this
disease.
The recent finding of driver genomic alterations in
BRAF gene in LGG and the development of new mole-
cules that interfere with this deregulated signaling are
highly attractive, especially in patients with midline, unre-
sectable tumours, and when RT is not recommended,
in order to overcome treatment limitations and improve
cure rate.
In 2008, different groups identified gains at 7q34 of
approximately 2 megabases in size in most LGG, repre-
senting segmental duplications of the region [1,2,16-18].
This duplication leads to the formation of a fusion be-
tween the KIAA1549 locus and BRAF and the resultingprotein displays a constitutively activated kinase activity
causing an aberrant activation of the downstream MAPK/
ERK pathway. Subsequent studies revealed other, less
common, molecular alterations in BRAF gene driving
activation of the same pathway [3,19,20]: the most fre-
quent is the point mutation that occurs at codon 600
(BRAFV600E), firstly associated with several non-CNS
human tumors, that results in substitution of valine by
glutamic acid [21,22].
BRAFV600E mutation appears to be particularly asso-
ciated with paediatric GG where its status changes based
on the anatomical location. Although Schindler et al.
could not identify it, the mutation seems to be present
in a relatively high percentage of cases with brainstem
location [3,23-25].
The prognostic relevance of BRAF duplication/mutation
is not clear yet: some reports suggest an association with a
better outcome in children displaying BRAF fusion and a
trend toward a lower PFS in LGG expressing BRAFV600E
mutation while other groups could not confirm these fin-
dings [26-30]. Dahiya et al. revealed a significantly worse
recurrence-free survival of BRAFV600E-mutated GG com-
pared to negative tumors, suggesting a negative prognostic
role for this mutation in GG [8].
Novel therapies targeting the altered BRAF pathway
have been developed, including the oral drug Vemurafe-
nib. After showing impressive, although transient, results
on recurrent melanoma, it has been approved by the FDA
for the treatment of unresectable or metastatic melanoma.
The drug proved well tolerated so far in adults, with arth-
ralgia, rash, alopecia, fatigue, photosensitivity reaction,
nausea, pruritus and skin lesions reported as main tox-
icities [31]. Overall, a variety of skin toxicities has been
reported and therefore a careful examination is recom-
mended during treatment [32].
The use of an oral target therapy to control the disease
in children with unresectable LGG is highly suitable.
In vitro and in vivo studies of paediatric astrocytoma
cell lines expressing BRAFV600E mutation have been
performed and show that target inhibition of mutated
BRAF exerts an antiproliferative activity and slows tu-
mour growth, improving survival [4]. With this strong
supportive rationale, a safety and pilot efficacy clinical
trial of Vemurafenib against BRAFV600E mutant recur-
rent or refractory LGG in children has recently started
(ClinicalTrials.gov Identifier: NCT01748149). To the best
of our knowledge, only one report on the use of this drug
in pediatric low grade GG has been published and showed
encouraging results, in association with vinorelbine [33].
Taking into consideration all these evidences and the
persistent progression of our patient, we decided to evalu-
ate the presence of BRAFV600E mutation in order to
initiate treatment with Vemurafenib. Since no pharma-
cokinetic data nor toxicity analysis are available in the
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ment with the minimal dose that proved active in the adult
cohort, and maintained it in consideration of the results
shown [34]. The excellent, rapid and sustained response
documented in our child after 6 months of treatment
shows a relevant efficacy of this small-molecule inhibitor in
a challenging subcategory of LGG, although a longer
follow-up is required to define the long-term response to
this drug. Notably, our patient did not receive any other
concurrent chemotherapy, proving that the observed re-
sponse can be attributed exclusively to the BRAF inhibitor.
The lesson provided by the use of Vemurafenib in mel-
anoma patients, however, warns treatment [35]. Moreover,
in the context of malignant GG, few reports have proved a
not uniform activity of Vemurafenib [6]. Although not
clear yet, these diverse responses are likely related to the
complex genetic aberrations present in malignant gliomas
which might induce the overactivation of MAP kinase
through alternative pathways, regardless of the BRAF sta-
tus, and thus impair the efficacy of the treatment. Simi-
larly, the mechanisms underlying the acquired resistance
are multiple and not fully understood yet. Most of them
rely upon the alternative reactivation of the MAP kinase
signaling pathway through the mutational activation of
other key molecule of the pathway, such as NRAS, MEK1
or MEK2, or the occurrence of BRAF-V600E splice var-
iants [36-38]. Moreover, MAPK pathway-independent
mechanisms of resistance have been also suggested,
involving alterations that lead to the upregulation of
the PI3K-AKT signaling pathway [39]. Therefore, the
combination with either MEK, ERK or PI3K inhibitors
might be considered to overcome both intrinsic and
acquired resistance.
The optimal tolerance to the treatment and the advan-
tage of the oral administration represent relevant aspects
in the context of LGG as they reduce the burden of the
frequent hospitalization that these children and their
families face, sometimes for several years. It is important
to point out, however, that the induction of secondary
cutaneous lesions and the promotion of proliferation of
pre-malignant cells harboring RAS mutation in non-
cutaneous tissues, reported in some adult patients, raise
considerable concern, especially in the pediatric popu-
lation. Therefore, a careful case-specific consideration of
the risk/benefit ratio is mandatory until more detailed
documentation will be provided by clinical trials.
Conclusions
To our knowledge, this is the first case describing the
use of Vemurafenib as single agent in paediatric GG.
Our experience, although limited to a case report, and
the review of the literature underline the importance of
understanding the driver molecular alterations of LGG
to improve treatment strategies, through target therapies,and ultimately outcome of these patients. As specific
BRAF inhibitors are now available, the evaluation of BRAF
status in children with tumors not amenable of GTR
should be considered in order to offer a valuable thera-
peutic alternative. A wider molecular signature, moreover,
might be required in case of low response or relapse, in
order to further improve the activity by multiple targeting.
Large clinical trials are needed to further evaluate the phar-
macokinetic profile, safety and efficacy of BRAF inhibitor
in the treatment of LGG with this signature and the time
of suspension of this therapy, considering the possibility of
relapse/progression of disease at the end of treatment.
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